Armata Pharmaceuticals Grants Premium Options to CEO, Director Amid Bacteriophage Breakthroughs
Armata Pharmaceuticals 2026 option grants reveal executive confidence in its phage‑therapy pipeline—CEO awards, share price rally, and long‑term incentives highlighted.
3 minutes to read